← Back to Screener

UTHR Report

08-04-2026 | Analyze. Execute. Alpha.

Performance Framework

Revenue
Earning
Sentiment
Estimate
Short interest
Cdrs
Ta analysis (short term)
Ta analysis (long term)
Insiders action
Institutional conviction
Mf

Key Metrics & Valuation

Market Cap 25.76B$
Next Earning Release 2026-04-29 00:00:00 (NA days)
Correlation to Market 78.5%
Technical Trend Trending up
Current Ratio 6.6
Return on Equity 19.3%
PEG Ratio 1.2
EV/EBITDA 13.4
EV/Revenue 7.6
EV/FCF 23.3
Price to Earning Correlation 86.5%
Total R&D (5yr % of Rev) 23.2%
Institutional Holding 12931.0%

Earnings & Cash Flow

  • This quarter EPS is 24.0% related to same quarter last year.
  • Annual earning is 14.0% compared to last year.
  • EPS (ttm) in the last 4 quarters is trending up .
  • Annual average earning surprise in the last 5 years is -11.2%.
  • Earnings in the last 5 years, is trending up .
  • 3.0 of the last 4 quarters had positive surprise.

EBITDA

  • This quarter EBITDA is 23.6% related to same quarter last year.
  • EBITDA in the last 4 quarters, is trending up.
  • Annual EBITDA in the last 5 years, is trending up.

Free Cash Flow (FCF)

  • This quarter FCF is -3.7% related to same quarter last year.

Revenue/Income

Revenue

  • This quarter revenue is 7.4% related to same quarter last year.

Net Income

  • This quarter income is 20.9% related to same quarter last year.

Sentiment

News Sentiment

  • Short term: 76.1% positive, 0.0% negative.
  • Long term: 56.1% positive, 0.0% negative.

Short Interest

  • Short ratio (Days to cover): 5.6
  • Short as % of float: 8.6%
  • Float share amount is trending down.

Future Estimates

Revenue 3.7%
Net Income 4.6%
EPS -3.2%
Price Target Up Side 24.8%

Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Next earning release is on 2026-04-29 00:00:00, in NA days

Technical Analysis

Hourly Momentum

Daily Framework

Weekly Strategic

Interactive Chart

Additional Resources

  • Premium Analysis Locked
  • AI Analyst Reasoning


    Content Locked Premium Analysis Locked (Contact for Access)